Protalix Unveils Promising Gout Therapy Data at ACR 2026
A Glimmer of Hope for Gout Sufferers Uncontrolled gout patients may soon see a light at the end of the tunnel. Protalix BioTherapeutics (NYSE American: PLX) just rolled out data at the ACR Convergence 2026, underscoring the potential of their drug candidate, PRX-115. This revelation is a big deal for those grappling with gout that just won't quit, constantly pelted by...
Continue Reading